Project Grant K08CA303675
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $304K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Cancer Institute awarded the University of California Irvine $586,364 on April 7, 2026, for a Project Grant (R01CA308352) under the Cancer Biology Research program (CFDA 93.396). The research investigates Group 1 innate lymphoid cells (ILCs), particularly ILC1s, as a potential therapeutic approach to acute myeloid leukemia (AML). Prior work published by the recipient in Nature Immunology demonstrated that ILC1s from healthy donors induce the death of leukemia stem cells and block...
- The National Cancer Institute awarded the University of California, San Diego $663,998 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct mechanistic research on targeting the Type I interferon pathway to improve cancer therapy efficacy. The research investigates how ubiquitin specific protease 18 (USP18) negatively regulates interferon signaling in cancer cells and tests whether blocking USP18-mediated suppression of the interferon response can enhance the...
- The National Institutes of Health National Cancer Institute awarded The University of Texas Southwestern Medical Center $688,012 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel RPS23 inhibitors for the treatment of acute myeloid leukemia. The funded research develops ligands that bind the ribosomal protein RPS23 and activate the integrated stress response through the GCN2 kinase pathway, triggering apoptosis in leukemia cells. The investigator-led...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $700,338 on May 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define and override mechanisms of in vitro and clinical resistance to asciminib, the first highly active allosteric kinase inhibitor for chronic myeloid leukemia. The research addresses acquired resistance to asciminib, which is rapidly being adopted as frontline therapy for CML patients. The project will employ...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $399,829 to the University of Maryland, Baltimore on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop protein degradation strategies that overcome menin drug resistance in acute leukemias. The project addresses rapid drug resistance to menin inhibitors in clinical trials for MLL-rearranged (MLLR) leukemias, which carry a dismal prognosis...
- The National Cancer Institute awarded The Trustees of the University of Pennsylvania $434,969 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate type I interferon response and differentiation in FLT3-inhibitor persistent acute myeloid leukemia. The funded research develops genetically engineered mouse models of acute myeloid leukemia with inducible and reversible FLT3 mutations to understand cellular mechanisms that maintain FLT3-mutant clone persistence...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute awarded Baylor College of Medicine $108,214 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2026. The project investigates post-transcriptional regulation as a therapeutic vulnerability in acute myeloid leukemia. The work tests the hypothesis that EIF4A1 inhibition is an effective AML therapy capable of overcoming menin inhibitor resistance. Aim 1 involves generating novel mouse models of menin inhibitor-resistant adult and pediatric AML to...
- This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...
- The National Cancer Institute awarded the University of Virginia $192,887 on May 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on sphingolipid-guided stratification and therapeutic opportunities in acute myeloid leukemia. The project investigates sphingolipid metabolism as a mechanism to improve acute myeloid leukemia risk classification beyond genomic characterization. Prior work identified two AML patient subtypes distinguished by reciprocal abundance of...